Fig 1: High miR-1 expression correlates with decreased AML patient survival. (A) Significantly upregulated and downregulated miRNAs in FLT3-ITD + AML patient samples in TARGET dataset (hsa-miR-1-2 is represented with a yellow mark). (B) Significantly upregulated miRNAs in FLT3-ITD + patients compared to FLT3-ITD negative patients from TCGA patient samples. Patients from TCGA dataset were divided into 2 groups on the 50th percentile high and low based on their miR-1-1 (C) and miR-1-2 (E) expression. Patients with high miR-1-1(D) (n = 77) or miR-1-2 (F) (n = 77) have worse survival compared to patients with low miR-1-1 (n = 78) or miR-1-2 (n = 78). Unpaired two-tailed t-test. ****p = <0.0001. Log-rank (Mantel-Cox) test was used for survival plots. *p = <0.05 Patients in TCGA dataset were divided based on their mutation status in FLT3 gene (Negative (G) and Positive (H)) and survival analysis was performed based on their miR-1-2 expression status. Gehan-Breslow-Wilcoxon test was used for survival plots. *p = < 0.05.